Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al

por Skobieranda, Franck, Candler, Shawn, Macfadden, Wayne
Publicado 2022

APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moder...

por Viscusi, Eugene R, Skobieranda, Franck, Soergel, David G, Cook, Emily, Burt, David A, Singla, Neil
Publicado 2019

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine

por Nafziger, Anne N., Arscott, Kelly A., Cochrane, Kristina, Skobieranda, Franck, Burt, David A., Fossler, Michael J.
Publicado 2019

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Mode...

por Singla, Neil K., Skobieranda, Franck, Soergel, David G., Salamea, Monica, Burt, David A., Demitrack, Mark A., Viscusi, Eugene R.
Publicado 2019

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute p...

por Singla, Neil, Minkowitz, Harold S, Soergel, David G, Burt, David A, Subach, Ruth Ann, Salamea, Monica Y, Fossler, Michael J, Skobieranda, Franck
Publicado 2017

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study i...

por Bogan, Richard K, Thorpy, Michael J, Dauvilliers, Yves, Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Tang, Lihua, Skobieranda, Franck, Šonka, Karel
Publicado 2020

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Wi...

por Bogan, Richard K, Thorpy, Michael J, Dauvilliers, Yves, Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Tang, Lihua, Skobieranda, Franck, Šonka, Karel
Publicado 2021

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized wi...

por Bogan, Richard K, Thorpy, Michael J, Dauvilliers, Yves, Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Tang, Lihua, Skobieranda, Franck, Šonka, Karel
Publicado 2021

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications

por Dauvilliers, Yves, Šonka, Karel, Bogan, Richard K., Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Chen, Abby, Black, Jed, Skobieranda, Franck, Thorpy, Michael J.
Publicado 2022

Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications

por Dauvilliers, Yves, Šonka, Karel, Bogan, Richard K., Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Chen, Abby, Black, Jed, Skobieranda, Franck, Thorpy, Michael J.
Publicado 2022